drugset / Trial / NCT02634437

Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects

NCT02634437

Phase 1 Completed 19 enrolled Allergan
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study is designed to observe the effect of renal function on the pharmacokinetic, safety, and tolerability profiles of Ulipristal acetate following administration of a single oral dose of a 10 mg Ulipristal acetate tablet.

Timeline

Start
2015-12-01
Primary completion
2016-12-09
Completion
2016-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulipristal Acetate Unknown 10 mg Oral